RA CAPITAL MANAGEMENT L P
Q2 2023 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001346824
· CRD 160174
· SEC-registered investment adviser
$5.3B Reported Value Total
RA CAPITAL MANAGEMENT, LP reports 9 total accounts under management (AUM). There are 9 discretionary accounts valued at $9,650,336,033, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
6 funds
· $16.3B gross asset value
Hedge Fund: $14.5B · Venture Capital Fund: $1.8B
Source: Form ADV filed 2026-03-31
Reported value
$5.3B
Quarter over quarter
+14.4%
Holdings
54
Top-10 concentration
58.3%
Key People
Form ADV owners & control persons
Richard H. (mi Only) Aldrich
PARTNER
Peter (nmn) Kolchinsky
PORTFOLIO MANAGER
Craig Alan Randall
GENERAL COUNSEL
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $5.3B |
| Positions | 54 |
| Change in reported value | +19.9% |
| New positions | 4 |
| Exited positions | 9 |
| Position turnover | 20.6% |
| Top-10 concentration | 58.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
84 | $11.5B |
|
Q1 2026 13F
Filed May 15, 2026
|
85 | $9.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
71 | $9.8B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
67 | $8.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
63 | $5.9B |
|
Q1 2025 13F
Filed May 15, 2025
|
85 | $6.0B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
89 | $7.5B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
81 | $8.7B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
78 | $7.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
76 | $7.9B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
62 | $6.4B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
66 | $5.1B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
54 | $5.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
59 | $4.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
70 | $4.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
81 | $4.7B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
88 | $3.8B |
|
Q1 2022 13F
Filed May 16, 2022
|
96 | $4.6B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
97 | $5.7B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
95 | $7.2B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | $1.0B | 18.92% |
| 2 | LEGN LEGEND BIOTECH CORP | $432.5M | 8.16% |
| 3 | PCVX VAXCYTE INC | $394.1M | 7.44% |
| 4 | DICE DICE THERAPEUTICS INC | $365.0M | 6.89% |
| 5 | ETNB 89BIO INC | $216.4M | 4.08% |
| 6 | BIIB BIOGEN INC | $151.8M | 2.87% |
| 7 | AVTE AEROVATE THERAPEUTICS INC | $141.7M | 2.68% |
| 8 | VRNA VERONA PHARMA PLC | $133.6M | 2.52% |
| 9 | CVAC CUREVAC N V | $127.6M | 2.41% |
| 10 | TYRA TYRA BIOSCIENCES INC | $123.2M | 2.33% |
| 11 | NAMS NEWAMSTERDAM PHARMA COMPANY | $107.0M | 2.02% |
| 12 | CTKB CYTEK BIOSCIENCES INC | $105.0M | 1.98% |
| 13 | JANX JANUX THERAPEUTICS INC | $102.9M | 1.94% |
| 14 | GERN GERON CORP | $101.3M | 1.91% |
| 15 | INBX INHIBRX INC | $100.0M | 1.89% |
| 16 | RYTM RHYTHM PHARMACEUTICALS INC | $93.6M | 1.77% |
| 17 | DAWN DAY ONE BIOPHARMACEUTICALS I | $93.2M | 1.76% |
| 18 | RXST RXSIGHT INC | $87.9M | 1.66% |
| 19 | COGT COGENT COMMUNICATIONS HLDGS | $76.0M | 1.43% |
| 20 | PEPG PEPGEN INC | $72.7M | 1.37% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.